Lieneke M. Ariens

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Paraneoplastic syndromes: the importance of early recognition and treatment

Paraneoplastic syndromes: the importance of early recognition and treatment

Journal: Nederlands tijdschrift voor geneeskunde

Published: June 02, 2026

Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry.

Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry.

Journal: Acta dermato-venereologica

Published: August 16, 2021

Conjunctival inflammation in dupilumab-treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study.

Conjunctival inflammation in dupilumab-treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study.

Journal: Allergy

Published: March 11, 2021

Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis.

Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis.

Journal: The journal of allergy and clinical immunology. In practice

Published: June 24, 2020

EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.

EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.

Journal: Allergy

Published: May 20, 2020

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.

Journal: Journal of the American Academy of Dermatology

Published: April 04, 2020

Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry.

Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry.

Journal: Allergy

Published: February 10, 2020

Dupilumab facial redness: Positive effect of itraconazole.

Dupilumab facial redness: Positive effect of itraconazole.

Journal: JAAD case reports

Published: November 05, 2019

Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.

Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.

Journal: Allergy

Published: May 25, 2019

Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.

Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.

Journal: Acta dermato-venereologica

Published: May 18, 2019

Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment.

Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment.

Journal: Acta dermato-venereologica

Published: May 11, 2019

Successful Treatment with Dupilumab in a Patient with Severe, Difficult to Treat Atopic Dermatitis: Beware of Symptomatic Adrenal Insufficiency due to Abrupt Discontinuation of Potent Topical Corticosteroids.

Successful Treatment with Dupilumab in a Patient with Severe, Difficult to Treat Atopic Dermatitis: Beware of Symptomatic Adrenal Insufficiency due to Abrupt Discontinuation of Potent Topical Corticosteroids.

Journal: Acta dermato-venereologica

Published: June 09, 2018

Showing 1-12 of 15

Last Updated: 09/26/2026